Indication
Congenital Hyperinsulinism
8 clinical trials
8 products
Clinical trial
A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Completed, Estimated PCD: 2020-08-31
Product
DasiglucagonProduct
HM15136Clinical trial
A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
dasiglucagonClinical trial
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Completed, Estimated PCD: 2022-03-07
Product
PlaceboClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients With Congenital HyperinsulinismStatus: Recruiting, Estimated PCD: 2025-04-04
Product
RZ358Product
18F-DOPAProduct
FurosemideClinical trial
Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic HypoglycemiaStatus:
Clinical trial
18F-Fluoro-L- DOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismStatus: Recruiting, Estimated PCD: 2023-12-31
Product
18F-Fluoro Dopa